Biotech Investing Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Biotech Investing Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Biotech Investing Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
Biotech Investing Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Biotech Investing Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Silver Dollar Samples Up to 2,753 g/t AgEq in Underground Sampling Campaign at its La Joya Silver Project
